Clinical Trial Update: Efficacy and Safety of NVC-422 in the Treatment of Adenoviral Conjunctivitis [Phase 2]

View source ↗

Summary

Phase 2 trial results evaluate the efficacy and safety of NVC-422 for adenoviral conjunctivitis; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenoviral Conjunctivitis

Drugs mentioned

• NVC-422

Snippet

Sponsor: NovaBay Pharmaceuticals, Inc. | Conditions: Adenoviral Conjunctivitis | Phase 2 | Status: COMPLETED